PYXS — Pyxis Oncology Share Price
Last trade - 00:00- $78.05m
- -$48.78m
- $16.15m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.65 | ||
| Price to Tang. Book | 0.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -64.13% | ||
| Return on Equity | -62.75% | ||
| Operating Margin | -554.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 16.15 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Directors
- Lara Sullivan CEO
- Pamela Connealy CFO (59)
- Ritu Shah COO
- Ronald Herbst CSO
- James Mutamba VBD
- Martina Molsbergen OTH (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 11th, 2018
- Public Since
- October 8th, 2021
- No. of Shareholders
- 52
- No. of Employees
- 44
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 61,947,665
- Address
- 321 Harrison Avenue, BOSTON, 02118
- Web
- https://pyxisoncology.com/
- Phone
- +1 6172219059
- Auditors
- Ernst & Young LLP
Latest News for PYXS
Upcoming Events for PYXS
Q1 2025 Pyxis Oncology Inc Earnings Release
Pyxis Oncology Inc Annual Shareholders Meeting
Pyxis Oncology Inc Annual Shareholders Meeting
Q2 2025 Pyxis Oncology Inc Earnings Release
Similar to PYXS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 22:48 UTC, shares in Pyxis Oncology are trading at $1.26. This share price information is delayed by 15 minutes.
Shares in Pyxis Oncology last closed at $1.26 and the price had moved by -71.43% over the past 365 days. In terms of relative price strength the Pyxis Oncology share price has underperformed the S&P500 Index by -74.24% over the past year.
The overall consensus recommendation for Pyxis Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePyxis Oncology does not currently pay a dividend.
Pyxis Oncology does not currently pay a dividend.
Pyxis Oncology does not currently pay a dividend.
To buy shares in Pyxis Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.26, shares in Pyxis Oncology had a market capitalisation of $78.05m.
Here are the trading details for Pyxis Oncology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PYXS
Based on an overall assessment of its quality, value and momentum Pyxis Oncology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pyxis Oncology is $7.20. That is 471.43% above the last closing price of $1.26.
Analysts covering Pyxis Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$1.12 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pyxis Oncology. Over the past six months, its share price has underperformed the S&P500 Index by -66.34%.
As of the last closing price of $1.26, shares in Pyxis Oncology were trading -47.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pyxis Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pyxis Oncology's management team is headed by:
- Lara Sullivan - CEO
- Pamela Connealy - CFO
- Ritu Shah - COO
- Ronald Herbst - CSO
- James Mutamba - VBD
- Martina Molsbergen - OTH